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Abstract
A20 [also known as TNFAIP3 (tumour necrosis factor α-induced protein 3)] restricts and terminates
inﬂammatory responses through modulation of the ubiquitination status of central components in NF-κB
(nuclear factor κB), IRF3 (interferon regulatory factor 3) and apoptosis signalling cascades. The phenotype
of mice with full or conditional A20 deletion illustrates that A20 expression is essential to prevent chronic
inﬂammation and autoimmune pathology. In addition, polymorphisms within the A20 genomic locus have
been associated with multiple inﬂammatory and autoimmune disorders, including SLE (systemic lupus
erythaematosis), RA (rheumatoid arthritis), Crohn’s disease and psoriasis. A20 has also been implicated
as a tumour suppressor in several subsets of B-cell lymphomas. The present review outlines recent
ﬁndings that illustrate the effect of A20 defects in disease pathogenesis and summarizes the identiﬁed
A20 polymorphisms associated with different immunopathologies.
Introduction
TheNF-κB (nuclear factor κB) family of transcription factors
plays a key role in controlling inflammatory and immune
responses [1]. NF-κB activation can proceed by two distinct
signalling cascades. Canonical NF-κB signalling is induced in
response to pro-inflammatory cytokines [e.g. TNF (tumour
necrosis factor)] and microbial infection and induces the
expression of mainly pro-inflammatory and survival genes,
whereas non-canonical NF-κB signalling is initiated by a
subset of receptors (e.g. lymphotoxin β) andmainly regulates
the development of lymphoid organs and adaptive immune
responses [2]. Because A20 has been described as a regulator
of canonicalNF-κB signalling, the focus of the present review
is on this pathway. In the canonical pathway, NF-κB dimers
are sequestered in the cytoplasm by binding to IκB (inhibitor
of NF-κB) proteins, of which IκBα is the best known. Upon
encountering an inflammatory stimulus such as TNF or LPS
(lipopolysaccharide), IκBα is phosphorylated followed by its
ubiquitination and proteasomal degradation, releasing NF-
κB for migration to the nucleus where it can drive gene
expression [1]. Different receptors activate distinct NF-κB
signalling pathways, which all converge at a central IKK (IκB
kinase) complex composed of two related kinases, IKK1 and
IKK2 (also known as IKKα and IKKβ), and a regulatory
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subunit NEMO (NF-κB essential modulator, also known as
IKKγ ).
Defects in the regulation of NF-κB-dependent gene
expression contribute to a variety of diseases, including in-
flammatory and autoimmune diseases, neurological disorders
and cancer. A tight regulation of NF-κB signalling is thus
absolutely required. To achieve this, cells employ different
control mechanisms to keep NF-κB signalling in check [3].
In this context, the ubiquitin-editing proteinA20 [also known
as TNFAIP3 (TNFα-induced protein 3)] has been described
as a key player in the termination of NF-κB signalling and
pro-inflammatory gene expression [4].
A20/TNFAIP3 is a cytoplasmic zinc-finger protein that
is induced under inflammatory conditions and acts as a
negative-feedback regulator of NF-κB activation in response
to multiple stimuli, including TNF, IL (interleukin)-1, TLR
(Toll-like receptor) and NLR [Nod (nucleotide-binding
oligomerization domain)-like receptor] ligands. A20 was
also shown to control antiviral signalling by acting as a
negative regulator of IRF3 (interferon regulatory factor 3)
signalling [5]. In addition to its NF-κB and IRF3 inhibitory
properties, A20 is also a strong inhibitor of TNF-induced
apoptosis [6]. The physiological importance of A20 as an
anti-inflammatory protein is clearly demonstrated by the
phenotype of A20-deficient mice, which are cachexic and
develop severe multi-organ inflammation causing premature
lethality [7]. Although little is known on the molecular
mechanisms by which A20 controls apoptotic signalling,
A20’s NF-κB-inhibitory activities were shown to depend
on its ubiquitin-editing function. The N-terminus has
DUB (deubiquitinating) activity and can inhibit NF-κB
signalling by removing Lys63-linked polyubiquitin chains
from specificNF-κB signallingmolecules [8]. TheC-terminal
zinc-finger-containing domain, however, possesses E3
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Figure 1 Localization of polymorphisms associated with human immunopathologies in and around A20/TNFAIP3
The nine exons of human A20 are represented as black/grey boxes, with the intronic regions in between. Untranslated exons
are represented in grey. A schematic overview of the protein domains corresponding to speciﬁc exons of A20 is displayed
below the genomic structure. The N-terminal OTU (ovarian tumour) domain is essential for DUB activity and the C-terminal
zinc ﬁnger (ZF 1–7) domains mediate E3 ubiquitin-ligase activity.
ubiquitin-ligase activity, promoting Lys48-linked polyubi-
quitination followed by proteasome-mediated degradation
of its target [8]. Recently, A20 was also shown to affect
the ubiquitination status of signalling proteins by preventing
the interaction between E2 ubiquitin-conjugating enzymes
and E3 ubiquitin ligases via competitive binding [9].
More information on the molecular mechanisms of NF-κB
signalling and its regulation can be found elsewhere
(e.g. [6]).
A20 and intestinal mucosal biology
Our intestinal microbiome poses a serious challenge to
our immune system. The intestinal epithelium acts as a
permeable barrier for efficient absorption of nutrients,
but, at the same time, remains impermeable for luminal
antigens, bacteria and bacterial products. Luminal bacteria
are sensed by specialized innate immune receptors, called
PRRs (pattern-recognition receptors), which are expressed
by the epithelium and include TLRs, NLRs and C-type
lectin receptors. Basal PRR stimulation leads to homoeostatic
NF-κB signalling which does not cause spontaneous inflam-
mation, but regulates intestinal barrier stability, epithelial
proliferation, anti-microbial peptide production and anti-
apoptotic responses [10]. This protective function of NF-
κB in the intestinal epithelium is clearly demonstrated in
mice that specifically lack NEMO or both IKK1 and IKK2
in the intestinal epithelium, and which develop spontaneous
intestinal inflammation due to increased epithelial apoptosis,
leading to bacterial mucosal infiltration [11]. We showed
recently that specific deletion of A20 in the intestinal
epithelium also increased the sensitivity of the epithelium
to apoptosis [12]. Although these mice develop normally
without any sign of spontaneous intestinal inflammation,
they are hypersensitive to DSS (dextran sodium sulfate)-
induced colitis and are unable to recover from DSS-induced
intestinal damage. This DSS-hypersensitivity is associated
with increased epithelial apoptosis [12]. Additionally, low-
dose TNF injection causes massive epithelial apoptosis,
leading to bacterial infiltration, bacteraemia and lethal
sepsis within hours [12]. Interestingly, A20 expression is
low at birth, and is strongly induced when the intestine
becomes colonized by commensal bacteria [13]. In agreement
with our observations in enterocyte-specific A20-deficient
mice, it was shown that lethal inflammation in full A20-
knockout mice is also triggered by the bacterial commensal
flora initiating pro-inflammatory cytokine production and
systemic inflammation [14]. Together, these data show that
A20 in enterocytes mainly acts as a cytoprotective protein
and suggest that defects in A20 expression or function could
contribute to intestinal pathology.
Evidence for a role of A20 in human intestinal pathology
also came from recent genetic studies identifying A20 as a
susceptibility locus for IBD (inflammatory bowel disease)
(Table 1 and Figure 1). A linkage analysis study on 260 IBD
patients from 139 Caucasian families associated a region of
human chromosome 6q, containing the A20 gene, to IBD
[15]. In addition, a GWAS (genome-wide association study)
for seven major common inflammatory diseases, on British
people by the Wellcome Trust Case Control Consortium,
identifiedA20 as a susceptibility gene forCrohn’s disease [16].
Expression analysis on mucosal biopsies from 69 Crohn’s
disease patients confirmed a consistent down-regulation of
A20 [17], further indicating reduced or defectiveA20 function
in IBD. Recently, a novel non-synonymous mutation in
African-American patients in exon 3 (A125V) was found
to be associated with increased risk of IBD, whereas the
same mutation was protective for SLE (systemic lupus
erythaematosis) [18]. Computer modelling predicted that
this amino acid change could alter the DUB activity of
A20, affecting its proper function [18]. Interestingly, an SNP
(single nucleotide polymorphism) in the A20 locus was also
C©The Authors Journal compilation C©2011 Biochemical Society
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Table 1 Genetic variants in or near A20/TNFAIP3 (138188581–138204449) associated with different immunopathologies in humans
(based on NCBI SNP database)
SNP Location Nucleotide Position Disease association Population
rs13207033 223 kb upstream A/G 137965418 RA American [26]
rs13192841 221 kb upstream A/G 137967214 SLE European [24]
rs2327832 215 kb upstream A/G 137973068 Coeliac disease European [19–21]
RA European [21,25,43]
rs10499194 186 kb upstream C/T 138002637 RA European/African-American
[44], American [26],
European [43,45,46]
Juvenile idiopathic arthritis [47]
SLE/RA* Japanese [48]
Type 1 diabetes European [28]
rs6920220 182 kb upstream A/G 138006503 RA American [26], European
[25,45,46,49],
European/African-
American [44]
Juvenile idiopathic arthritis [47]
Type 1 diabetes European [28]
SLE European [23]
rs7753394 103 kb upstream C/T 138085248 Crohn’s disease European [16]
rs10499197 56 kb upstream G/T 138132516 SLE European [23]
rs5029930 Intron 1 A/C 138190684 Coronary artery disease
in Type 2 diabetes
American [50]
rs5029937 Intron 2 G/T 138195151 RA European [46,51]
rs5029939 Intron 2 C/G 138195723 Systemic sclerosis European [52]
SLE European [23],
African-American [18]
rs5029941 Exon 3 C/T (A125V) 138196060 SLE/IBD† African-American [18]
rs2230926 Exon 3 T/G (F127C) 138196066 SLE European [24,53],
African-American [18],
Japanese [54], Chinese
[30]
SLE/RA Japanese [48]
Sjo¨gren’s
syndrome/Crohn’s
disease/psoriasis/RA
European [22]‡
rs582757 Intron 5 A/G 138197824 Rheumatic heart disease Chinese [55]
New (no rs) Intron 5 C/− 138197889 RA European [22]‡
rs610604 Intron 6 A/C 138199417 Psoriasis Caucasian [34]
Coronary artery disease in
Type 2 diabetes
American [50]
rs5029953 Intron 7 A/G 138200760 SLE African-American [18]
rs7749323 26 kb downstream A/G 138230389 SLE European [23]
rs5029930 28 kb downstream A/C 138232377 Coronary artery disease in
Type 2 diabetes
American [50]
Polymorphic dinucleotide 68 kb downstream TT>A 138272732–138271733 SLE European/Korean [29]
rs6922466 256 kb downstream A/G 138444930 SLE European [24]
*Risk factor in Caucasian population, protective in Japanese population [48].
†Protective in SLE, risk factor for IBD in African-American population [18].
‡Additional SNPs were identiﬁed in multiple but unspeciﬁed autoimmune disease patients according to Musone et al. [22].
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identified as a risk factor in coeliac disease [19–21]. Finally,
the non-synonymous SNP rs2230926/F127C was found to
be associated with Crohn’s disease in a Caucasian population
with multiple autoimmune diseases [22] (Table 1).
In conclusion, the combined data from mouse disease
models and human IBD samples identify A20 as a protein
important for intestinal immune homoeostasis, and suggest
that A20 deficiency or dysfunction could sensitize for IBD
development. A20 restricts aberrant TLR- andNLR-induced
NF-κB signalling in mucosal immune cells in response to the
commensal microbiota, thereby preventing the production of
harmful pro-inflammatory cytokines, and preserves intestinal
barrier integrity in inflammatory conditions by preventing
enterocyte apoptosis. On the basis of these findings, local
enhancement of A20 function in the intestinal mucosa
might therefore be a promising therapeutic strategy for the
treatment of IBD.
A20 and autoimmune diseases
Next to the above described association of A20 with IBD
and coeliac pathology, several more polymorphisms in or
near the A20 locus were described as being associated
with inflammatory autoimmune pathology, including SLE
[23,24], RA (rheumatoid arthritis) [25,26], psoriasis, multiple
sclerosis [27] and Type 1 diabetes [28]. We recently
published an overview of, at that time, all known A20
polymorphisms associated with disease [4]. Many of these
have since been confirmed by multiple independent studies,
often with patient and control cohorts from different
populations. In addition, a number of new polymorphisms
and mutations have been identified through genetic studies.
An updated overview of the currently known disease-
associated polymorphisms in the A20 genomic locus is
provided in Table 1 and Figure 1.
Most of the disease-associated A20 polymorphisms reside
outside the A20 gene or in intronic sequences (Figure 1).
Only two non-synonymous SNPs were found, in very close
proximity in exon 3. These two SNPs (rs2230926/F127C
and rs5029941/A125V) both affect the N-terminal DUB
domain of A20, and functional studies on the SLE-associated
F127C and A125V mutations were found to result in
decreased inhibitory activity of A20 [18,24]. Using computer
models, the structural implications of both mutations were
predicted, showing that the A125V mutation could lead to
conformational changes affecting the nearby catalytic core
of the DUB domain, whereas the F127C mutation could
influence the binding of target proteins [18]. In a recent
study, all exons of TNFAIP3 were sequenced in a collection
of 123 individuals with multiple autoimmune diseases and
397 unrelated healthy controls, identifying 11 new coding
variants, of which eight are non-synonymous mutations
spread over the entire coding sequence [22]. This study also
identified the F127C coding SNP as a mutation associated
with the risk of Sjo¨gren’s syndrome,Crohn’s disease, psoriasis
and RA [22]. Additionally, a novel SLE-associated haplotype
(TT>A) was recently identified in a conserved regulatory
region downstream of A20, which results in reduced A20
expression. This polymorphism results in reduced DNA
binding of NF-κB protein complexes [29].
The SLE-associated SNP (rs2230926) was first identified
in Caucasians and was recently confirmed in a Chinese
Han population [30]. The same GWAS identified some new
SLE-susceptibility loci. One of the newly identified SNPs
(rs10036748) is located in the TNIP1 (TNFAIP3-interacting
protein 1), also known as ABIN1 (A20-binding inhibitor
of NF-κB) locus, an A20-binding inhibitor of NF-κB and
apoptosis signalling [31]. Another TNIP1 SNP (rs7708392)
associated with SLE risk was identified in a Caucasian
population [32] and confirmed in a Japanese population
[33]. Together with A20, TNIP1 was also identified as a
susceptibility gene for psoriasis [34]. It is worth mentioning
that several genetic loci have been associated with more than
one immunopathology, and many autoimmune patients are
affected by multiple autoimmune diseases [22] (Table 1).
A20 and B-cell biology
Persistent NF-κB activation has a critical role in cancer
development and progression [35]. Different genetic studies
have suggested a role for A20 as a tumour suppressor, since
A20 inactivation by somatic mutations and/or deletions,
leading to constitutive NF-κB activation, is a frequent event
in several subsets of B-cell lymphomas [36–39].
To study the role of A20 in lymphomagenesis, we and
others generated B-cell-lineage-specific A20-knockout mice
[40–42]. All three studies show that B-cell-specific A20
deficiency enhancesB-cell proliferation and survival and leads
to an autoimmune pathology, but does not lead to the spon-
taneous development of B-cell lymphomas. A20-deficient
B-cells show increased CD40-, BCR- (B-cell receptor) and
TLR-inducedNF-κBresponses in vitro [40–42].Remarkably,
according to Tavares et al. [40], A20-deficient B-cell survival
results from the resistance of B-cells to Fas-induced apoptosis
due to increased NF-κB-dependent expression of the anti-
apoptotic protein Bcl-x. Moreover, their mice developed a
lupus-like autoimmune pathology characterized by elevated
numbers of germinal centre B-cells, autoantibodies and
glomerular immunoglobulin deposits [40]. In contrast with
these findings, studies with our A20-deficient mice show
development of a progressive inflammatory phenotype,
leading to an autoimmune syndrome only in old mice [41].
These mice do not display significant levels of antibodies
against nuclear self-antigens (ANAs), which are the most
common autoantibodies observed in SLE, but a general
IgG autoreactivity to cardiolipin (diphosphatidylglycerol),
a common autoantigen in autoimmune disease [41].
The fact that B-cell-specific A20-knockout mice do not
develop B-cell lymphomas in naive conditions suggests that
A20 deficiencymay sensitize to lymphomagenesis only in co-
operation with other B-cell oncogenes. Future studies should
providemore insight into this aspect to clarify the role of A20
as a tumour suppressor in B-cells.
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Concluding remarks
A20 exerts both NF-κB-inhibitory, IRF3-inhibitory and
anti-apoptotic activities. GWASs have identified A20 as
a susceptibility gene for IBD, multiple autoimmune
pathologies and subsets of B-cell lymphomas, and suggest
that defects in A20 expression or function may contribute
to disease pathogenesis. Although these genetic studies
clearly define A20 as a disease-susceptibility gene, more
functional studies are needed to clarify the importance
of A20 in disease pathogenesis. Mice lacking A20 in
specific cell types or expressing mutant versions of A20 are
important tools in these studies and will be very helpful to
clarify the mechanisms by which A20 exerts its protective
actions. Data from full A20-knockout mice suggest that
the lethal phenotype is the consequence of uncontrolled
innate immune responses triggered by intestinal bacteria,
underscoring an essential anti-inflammatory function of A20
in these cells [7,14]. In contrast, A20 is dispensable for
intestinal tissue development and enterocyte homoeostasis,
but essential as a protective protein in conditions of
inflammatory pressure [12]. A20 deficiency in B-cells does
not lead to lymphomagenesis, but increases B-cell responses
and survival, leading to the development of autoimmune
pathology [40,41]. Future studies using tissue- and cell-
specific A20-knockout mice will help to clarify further the
role of A20 in autoimmune and inflammatory pathology.
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